RxDoctor Payments Data

Ruben de Los Santos, MD

Internal Medicine · Eagle Pass, TXNPI 1467534008

Payments from drug & device makers

$3,210in general payments, 2019–2025

Across 114 payments — averaging $28.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$735
  • Mimedx Group, Inc.$604
  • Johnson & Johnson$399
  • Organogenesis Inc.$295
  • Novo Nordisk$238
  • Pfizer$146
  • plus $793 from 17 others

What the payments were for

  • Food & beverage$3,18099%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,210 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$372,730
Medicare patients
362
Services billed
4,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate278$264,672
EliquisApixaban271$234,898
FarxigaDapagliflozin Propanediol123$150,599
OzempicSemaglutide107$115,776
JanumetSitagliptin Phos/Metformin Hcl87$97,750
MyrbetriqMirabegron101$89,548
EntrestoSacubitril/Valsartan75$62,367
XifaxanRifaximin14$54,611
JardianceEmpagliflozin30$49,021
LinzessLinaclotide22$29,688
SantylCollagenase Clostridium Hist.49$28,675
Celecoxib533$27,026
TradjentaLinagliptin23$25,705
VelphoroSucroferric Oxyhydroxide21$25,387
Sucralfate204$23,355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Janumet Xr$87$373,868376 claims
PfizerEliquis$146$234,898271 claims
AstraZenecaFarxiga, Lokelma, Breztri Aerosphere$735$168,866154 claims
Novo NordiskOzempic, Levemir$238$123,070146 claims
NovartisEntresto$105$62,36775 claims
AbbVieLinzess$22$29,68822 claims
Smith+NephewSantyl$28$28,67549 claims
Johnson & JohnsonXarelto$399$21,07313 claims
Sanofi-aventis U.S. LLCLantus$38$5,23158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Eagle Pass

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →